EUVIMEDEUVIMED entdecken
Open Access · CC BY 4.0

Alzheimer's Disease Co‐Pathology and Cognitive Impairment in Amyotrophic Lateral Sclerosis

Elisabeth Kasper iD, Annaliis Lehto iD, Alexandra Jürs iD, Nina Nordmann, Oliver Peters, Julian Hellmann, Josef Priller, Eike Jakob Spruth, Gabor C Petzold iD, Ina Voigt, Patrick Weydt, Sarah Bernsen und 18 weitere

Annals of Neurology · 2026-07 · 100 (1) · 123-138

DOI: 10.1002/ana.78227 ↗

Kurz gefasst

Fachartikel in der Zeitschrift Annals of Neurology, online erschienen am 11.05.2026. Verfasst von Elisabeth Kasper und 29 weiteren Autor:innen. Beteiligte Einrichtung: Department of Neurology, Rostock University Medical Center, Rostock, Germany. Hauptthemen laut MEDLINE: Amyotrophic Lateral Sclerosis, Alzheimer Disease, Cognitive Dysfunction. Die Arbeit wurde bisher 4-mal zitiert (Crossref) und nennt 45 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0).

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Objectives

Amyotrophic lateral sclerosis (ALS) and Alzheimer's disease (AD) share neuropathological features, including tau, amyloid, and TDP‐43 pathology. This study investigated whether AD‐related pathological changes are associated with cognitive impairment ALS.

Methods

Cerebrospinal fluid (CSF total‐tau, phosphorylated‐tau, beta‐amyloid) and plasma biomarkers (TDP‐43; neurofilament light chain [NfL]) were analyzed in 192 individuals with ALS or ALS with frontotemporal dementia (ALS‐FTD) and 100 healthy controls. Cognitive performance was assessed using the Edinburgh Cognitive and Behavioral ALS Screen (ECAS). Group comparisons and regression analyses examined associations between biomarker profiles and cognitive status. Autopsy data were available for a subset of participants.

Results

Compared with healthy controls, patients with ALS – particularly those with cognitive impairment (ALSci) or ALS‐FTD – showed elevated AD‐related biomarkers. Significant differences in beta‐amyloid levels were observed between healthy controls (HCs) and patients with ALSci, but not between controls and cognitively unimpaired patients. CSF p‐tau and total‐tau levels were strongly associated with domain‐specific cognitive performance. In contrast, plasma extracellular vesicle TDP‐43 and NfL showed weak or no association with cognition. In vivo biomarkers alone reliably distinguished cognitive impairment only in ALSci and ALS‐FTD. Postmortem analyses showed no strong association between ABC scores or overall TDP‐43 burden and cognitive state; however, temporal and hippocampal TDP‐43 burden was associated with cognitive dysfunction.

Interpretation

Our findings suggest that tau‐related CSF biomarkers, particularly p‐tau and total‐tau, are associated with cognitive deficits in ALS, indicating that AD‐related pathology might be associated to cognitive decline in ALS. However, postmortem data showed even stronger relation of TDP43 pathology to cognitive deficits in ALS. ANN NEUROL 2026;100:123–138

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Amyotrophic Lateral SclerosisAlzheimer DiseaseCognitive DysfunctionHumansFemaleMaletau ProteinsAgedDNA-Binding ProteinsAmyloid beta-PeptidesMiddle AgedBiomarkersNeurofilament ProteinsFrontotemporal Dementia

Substanzen

tau ProteinsDNA-Binding ProteinsAmyloid beta-PeptidesBiomarkersTARDBP protein, humanNeurofilament Proteinsneurofilament protein L

Autor:innen und Institutionen

  • Department of Neurology, Rostock University Medical Center, Rostock, Germany.
  • German Center for Neurodegenerative Diseases (DZNE), Rostock, Greifswald, Germany.
  • Translational Neurodegeneration Section "Albrecht-Kossel," Department of Neurology, Rostock University Medical Center, Rostock, Germany.
  • German Center for Neurodegenerative Diseases (DZNE), Berlin, Germany.
  • Charité - Universitätsmedizin Berlin, corporate member of Freie Universität Berlin and Humboldt-Universität zu Berlin-Institute of Psychiatry and Psychotherapy, Berlin, Germany.
  • Department of Psychiatry and Neurosciences, Charité Universitätsmedizin Berlin, Berlin, Germany.

ORCID-Profile: Elisabeth Kasper, Annaliis Lehto, Alexandra Jürs, Gabor C Petzold, Lukas Beichert, Stefan Teipel, Johannes Prudlo, Andreas Hermann

Zitieren

APA

Kasper, E., Lehto, A., Jürs, A., Nordmann, N., Peters, O., Hellmann, J., Priller, J., Spruth, E. J., Petzold, G. C., Voigt, I., Weydt, P., Bernsen, S., Dinter, E., Falkenburger, B., Günther, R., Düzel, E., Glanz, W., Synofzik, M., Beichert, L., …, & Hermann, A. (2026). Alzheimer's Disease Co‐Pathology and Cognitive Impairment in Amyotrophic Lateral Sclerosis. Annals of Neurology, 100(1), 123-138. https://doi.org/10.1002/ana.78227

Vancouver

Kasper E, Lehto A, Jürs A, Nordmann N, Peters O, Hellmann J, et al. Alzheimer's Disease Co‐Pathology and Cognitive Impairment in Amyotrophic Lateral Sclerosis. Annals of Neurology. 2026;100(1):123-138. doi:10.1002/ana.78227

BibTeX
@article{Kasper2026,
  author = {Kasper, Elisabeth and Lehto, Annaliis and Jürs, Alexandra and Nordmann, Nina and Peters, Oliver and Hellmann, Julian and Priller, Josef and Spruth, Eike Jakob and Petzold, Gabor C and Voigt, Ina and Weydt, Patrick and Bernsen, Sarah and Dinter, Elisabeth and Falkenburger, Björn and Günther, René and Düzel, Emrah and Glanz, Wenzel and Synofzik, Matthis and Beichert, Lukas and Spottke, Annika and Wagner, Michael and Brosseron, Frederic and Schmid, Matthias C and Halle, Annett and Herms, Jochen and Schneider, Anja and Teipel, Stefan and Prudlo, Johannes and Neumann, Manuela and Hermann, Andreas},
  title = {Alzheimer's Disease Co‐Pathology and Cognitive Impairment in Amyotrophic Lateral Sclerosis},
  journal = {Annals of Neurology},
  year = {2026},
  volume = {100},
  number = {1},
  pages = {123--138},
  doi = {10.1002/ana.78227}
}
Infokarte | EUVIMED

Artikeldaten derzeit nicht verfügbar.

Recherche